NEW YORK , Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it
Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics
Start Time: 08:30 January 1, 0000 8:58 AM ET BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - Pres
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, r
BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a thumbs-down to the company's investigat
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS.
The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers expressed doubts over the safety and efficacy of th
The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotrophic lateral sclerosis (ALS) therapy, sending the
BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly bet
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
NEW YORK , May 9, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a c
NEW YORK , March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold
NEW YORK , Nov. 7, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it w
Brainstorm Cell Therapeutics is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. NurOwn's mechanism of action relies on bringing down neuroinflammation and alteri
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE